Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

Phase 1

Completed

• Conditions: Ornithine Transcarbamylase Deficiency
• Interventions: Other: Placebo; Biological: ARCT-810

• Registration Number: NCT04442347
• Lead Sponsor: Arcturus Therapeutics, Inc.

Brief Summary

Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-810 in clinically stable patients (stable on standard of care treatment, e.g. diet ± ammonia scavengers) with ornithine transcarbamylase deficiency (OTCD).

Detailed Description

This is a single ascending dose study of ARCT-810 in which approximately 12 (up to a maximum of 20) clinically stable patients with ornithine transcarbamylase deficiency (OTCD) are planned to be enrolled.

Each study subject's participation length is approximately 8 weeks, from screening through last study visit. The study comprises an up to 4-week screening period, and a 4-week diet run-in period, to occur concurrently, followed by a 1-day dosing period and a 28-day post-treatment period.

Study participants will be allocated to one of the three single-dose treatment groups (also referred to as cohorts), to test different doses of ARCT-810. Four subjects will be enrolled in each group. Within each cohort, subjects will be randomized 3:1 to receive ARCT-810 or placebo as an IV infusion.

Study Timeline

• Study First Submitted: 2020-06-19
• Study First Submitted QC: 2020-06-19
• Study First Posted: 2020-06-22
• Study Start: 2020-11-03
• Primary Completion: 2023-08-30
• Study Completion: 2024-04-30
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-31
• Last Update Posted: 2024-08-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

1. Adequate cognitive ability to consent and recall symptoms over a 1-week time period

2. Males and females ≥18 years of age with documented diagnosis of ornithine transcarbamylase deficiency (OTCD) confirmed with genetic testing, or willing to consent to OTC gene sequencing and deletion/duplication testing

3. Subject's ornithine transcarbamylase deficiency (OTCD) is stable as evidenced by

   1. no clinical symptoms of hyperammonemia AND
   2. an ammonia level <100 µmol/L (170 µg/dL) at the screening evaluation

   Subjects must remain free from symptoms of hyperammonemia throughout the screening period.

4. If using nitrogen ammonia scavenger therapy, must be on a stable regimen (no change in dose or frequency) for ≥ 28 days prior to providing informed consent and throughout the screening period

5. Must have maintained a stable protein-restricted diet (+/- amino acid supplementation) for at least 28 days prior to providing informed consent and continue to maintain a stable diet for the duration of the study

6. Good general health other than OTCD, in the opinion of the Investigator

7. Willing to refrain from strenuous exercise/activity and alcohol for 72 hours before study visits

8. Willingness to comply with procedures and visits

9. Willingness to follow contraception guidelines

Read More

Exclusion Criteria

1. History of clinically significant disease(s), in the opinion of the Investigator
2. Clinically significant screening laboratory values
3. Uncontrolled diabetes
4. Clinically significant anemia
5. Subjects who develop infection during screening must be asymptomatic for at least 7 days prior to dosing
6. Unwillingness to comply with study requirements
7. History of positive HIV, hepatitis C, or chronic hepatitis B
8. Uncontrolled hypertension
9. Malignancy within 5 years prior to study
10. Treatment with another investigational drug, biological agent, or device within 30 days of screening, or 5 half-lives of investigational drug
11. Treatment with any oligonucleotide or mRNA within 6 months of screening, with exceptions for some vaccinations and investigational treatments
12. History of gene therapy, hepatocyte or mesenchymal stem cell transplantation
13. Prior organ transplant
14. History of severe allergic reaction to a liposomal product
15. Recent history of, or current, drug or alcohol abuse
16. Dependence on inhaled (smoked or vaped) or oral cannabis products
17. Systemic corticosteroids within 6 weeks prior to screening
18. Blood donation of 50 to 499 mL within 30 days of screening or of .499 mL within 60 days of screening
19. Other conditions, in the opinion of the Investigator, that would make the subject unsuitable for participation

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Single doses of 0.9% Saline administered intravenously
ARCT-810	ARCT-810	Ascending single doses of ARCT-810 administered intravenously

Primary Outcome Measures

Name	Time	Method
Incidence, severity and dose-relationship of adverse events (AEs)	4 weeks	Safety and tolerability of ARCT-810 assessed by determining the incidence, severity and dose-relationship of AEs by dose

Secondary Outcome Measures

Name	Time	Method
T1/2 after single dose of ARCT-810	Up to 4 weeks	Terminal half-life
Maximum observed plasma concentration (Cmax) after single dose of ARCT-810	Up to 4 weeks	The maximum observed plasma concentration (Cmax)
AUC0-inf after single dose of ARCT-810	Up to 4 weeks	AUC from time zero extrapolated to infinity
MRT0-inf after single dose of ARCT-810	Up to 4 weeks	The mean residence time extrapolated to infinity
Time at which Cmax occurred after single dose of ARCT-810	Up to 4 weeks	The time at which Cmax occurred (Tmax)
Change in area under the curve after single dose of ARCT-810	Up to 4 weeks	Area under the plasma concentration versus time curve (AUC) from time zero to the last quantifiable time point
AUCExtrap after single dose of ARCT-810	Up to 4 weeks	The relative portion of AUC0-inf extrapolated beyond AUC0-t
Vss after single dose of ARCT-810	Up to 4 weeks	Volume of distribution
CL after single dose of ARCT-810	Up to 4 weeks	Total body clearance, calculated as dose divided by AUC0-inf

Trial Locations

Locations (8)

University of Florida; 🇺🇸 Gainesville, Florida, United States

University of Utah; 🇺🇸 Salt Lake City, Utah, United States

Children's Wisconsin - Milwaukee Hospital; 🇺🇸 Milwaukee, Wisconsin, United States

M Health Fairview Masonic Children's Hospital; 🇺🇸 Minneapolis, Minnesota, United States

The Mount Sinai Hospital; 🇺🇸 New York, New York, United States

University of Texas Southwestern Medical Center at Dallas; 🇺🇸 Dallas, Texas, United States

Children's Hospital of Pittsburgh; 🇺🇸 Pittsburgh, Pennsylvania, United States

Baylor University; 🇺🇸 Waco, Texas, United States